TrialMultiple sclerosis (Houndmills, Basingstoke, England)2024

Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.

Xavier Montalban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.